Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 937 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Lianne Gensler ², Atul Deodhar ³, Xenofon Baraliakos ⁴, Denis Poddubnyy ⁵, Alan Kivitz ⁶, Marga Oortgiesen ⁷, Dominique Baeten ⁸, Nadine Goldammer ⁹, Jason Coarse ⁷, MK Farmer ⁷ and Maxime Dougados ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
Abstract Number: 1536 • 2019 ACR/ARP Annual Meeting
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Francisco Ramírez-Valle¹, Mary Adams ¹, Lisa Beebe ², Jian Chen ¹, Claudio Chuaqui ¹, Jamie Connarn ¹, Alan Corin ¹, Karen Dingley ¹, J. Michael Ellis ¹, Rajula Gaur ¹, Lawrence Hamann ¹, John Malona ¹, Kofi Mensah ¹ and Maria Palmisano ¹, ¹Celgene Corporation, Summit, NJ, ²Celgene Corporation, Cambridge, MA
Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating…
Abstract Number: 598 • 2019 ACR/ARP Annual Meeting
Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis
Weiping Kong¹, Caroline Jefferies ², Tom Learch ², Feng Zhu ¹, Nan Zhang ¹, Dier Jin ¹, Yingze Zhang ¹, Qingwen Tao ¹, Xiaoping Yan ¹, Michael Weisman ³ and Mariko Ishimori ², ¹China-Japan Friendship Hospital, Beijing, China (People's Republic), ²Cedars-Sinai Medical Center, Los Angeles, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Spinal structural damage can lead to physical dysfunction and decline of spinal mobility in patients with ankylosing spondylitis (AS). Although great progress has been…
Abstract Number: 1010 • 2019 ACR/ARP Annual Meeting
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Tobias Russell¹, Abdulla Watad ², Charlie Bridgewood ³, Almas Khan ⁴, Abhay S Rao ⁴, Peter Loughenbury ⁴, Peter Milner ⁴, Robert Dunsmuir ⁴, Thomas Baboolal ³, Elena Jones ⁵, Richard Cuthbert ¹ and Dennis McGonagle ⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, England, United Kingdom, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) is associated with entheseal inflammation and new bone formation. Resident populations of lymphocytes have been identified at the enthesis that on…
Abstract Number: 1542 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Proton Rahman ¹, Derek Haaland ², Dalton Sholter ³, Michael Starr ⁴, Arthur Karasik ⁵, Michelle Teo ⁶, Sanjay Dixit ⁷, Ariel Masetto ⁸, Anna Jaroszynska ⁹, Pauline Boulos ⁷, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Waterside Clinic, Barrie, ON, Canada, ³Rheumatology Associates, Edmonton, AB, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵., Toronto, ON, Canada, ⁶Balfour Medical Clinic, Penticton, BC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹., Oakville, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trial and usually varies over time. The purpose…
Abstract Number: 603 • 2019 ACR/ARP Annual Meeting
Are the Modified New York and ASAS Criteria Interchangeable in the Classification of Patients with Spondyloarthritis with Radiographic Sacroiliitis?
Anne Boel¹, Anna Moltó ², Désirée van der Heijde ³, Adrian Ciurea ⁴, Maxime Dougados ⁵, Lianne Gensler ⁶, Maria José Santos ⁷, Eugenio de Miguel ⁸, Denis Poddubnyy ⁹, Martin Rudwaleit ¹⁰, Astrid van Tubergen ¹¹, Floris van Gaalen ³ and Sofia Ramiro ¹², ¹Leiden University Medical Centre, Leiden, Netherlands, ²Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ³Leiden University Medical Center, Leiden, Netherlands, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Cochin Hospital, Paris, France, ⁶University San Francisco California, San Francisco, CA, ⁷Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁸Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁹Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ¹⁰Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ¹¹Maastricht University Medical Centre and Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands, ¹²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands
Background/Purpose: Patients with axial spondyloarthritis (axSpA) with radiographic sacroiliitis may be classified using the modified New York (mNY) criteria as ankylosing spondylitis and using the…
Abstract Number: 1082 • 2019 ACR/ARP Annual Meeting
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Eunyoung Lee¹, Kyung-Do Han ², Yeong-Wook Song ³ and Eun Young Lee ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ²Department of Biostatistics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The aim of this study is to determine the risk of overall malignancy and site-specific cancer in ankylosing spondylitis (AS) patients compared with patients…
Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Ariel Masetto ², Michelle Teo ³, Pauline Boulos ⁴, Dalton Sholter ⁵, Suneil Kapur ⁶, Emmanouil Rampakakis ⁷, Meagan Rachich ⁸, Odalis Asin-Milan ⁸, Allen Lehman ⁸ and Francois Nantel⁸, ¹Memorial University, Newfoundland, NL, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷JSS Medical Research, Montreal, Canada, ⁸Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…
Abstract Number: 608 • 2019 ACR/ARP Annual Meeting
Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls
Freke Wink¹, Thomas Diemel ², Suzanne Arends ² and Anneke Spoorenberg ², ¹Medical Center Leeuwarden, Leeuwarden, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in…
Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Klaus Krüger¹, Sven Remstedt ², Astrid Thiele ³ and Ines Klaudius ⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…
Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Lykke Midtbøll Ørnbjerg ¹, Cecilie Heegaard Brahe¹, Anne Gitte Loft ², Johan Askling ³, Adrian Ciurea ⁴, Herman Mann ⁵, Servet Akar ⁶, Eirik Kristianslund ⁷, Dan Nordström ⁸, Maria José Santos ⁹, Catalin Codreanu ¹⁰, Manuel Pombo-Suarez ¹¹, Ziga Rotar ¹², Bjorn Gudbjornsson ¹³, Daniela DiGuiseppe ¹⁴, Michael J. Nissen ¹⁵, Karel Pavelka ⁵, Soner Senel ¹⁶, Joe Sexton ¹⁷, Kari K. Eklund ¹⁸, Anabela Barcelos ¹⁹, Ruxandra IONESCU ²⁰, Carlos Sánchez-Piedra ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Irene van der Horst-Bruinsma ²⁴, Gary Macfarlane ²⁵, Florenzo Iannone ²⁶, Brigitte Michelsen ¹, Lise Hyldstrup ²⁷, Niels Steen Krogh ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹¹Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ¹²UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹³Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁴Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ¹⁵University Hospital Geneva, Geneva, Switzerland, ¹⁶Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁷Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁸ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹⁹Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ²⁰SPITALUL CLINIC SFANTA MARIA, Bucharest, ²¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸Zitelab / DANBIO, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…
Abstract Number: 611 • 2019 ACR/ARP Annual Meeting
Retina of Ankylosing Spondylitis Patients Shows Early Signs of Atherosclerotic Disease in Comparison with Healthy Controls
Rianne van Bentum¹, Milad Baniaamam ², Buket Kinaci-Tas ³, Aleid van de Kreeke ⁴, Merve Kocyigit ¹, Pieter Jelle Visser ⁵, Erik Serné ⁶, Frank Verbraak ⁷, Mike Nurmohamed ⁸ and Irene van der Horst-Bruinsma ¹, ¹Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Rheumatology, Reade, Amsterdam|Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ³Opthalmology dpt., Amsterdam University Medical Center, location AMC, Amsterdam, Amsterdam, Netherlands, ⁴Ophthalmology dpt., Amsterdam University Medical Center, location VUmc, Amsterdam, Amsterdam, Netherlands, ⁵Dpt. of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam, Amsterdam, Netherlands, ⁶Dpt. Internal Medicine, Amsterdam University Medical Center, location VUmc, Amsterdam, Amsterdam, Netherlands, ⁷Ophthalmology dpt., Amsterdam University Medical Center, Amsterdam, Amsterdam, Netherlands, ⁸Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: Chronic systemic inflammation in patients with ankylosing spondylitis (AS) contributes to the development of cardiovascular disease (CVD). Early recognition of microvascular changes could improve…
Abstract Number: 1109 • 2019 ACR/ARP Annual Meeting
Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis
Xiaojian Ji ¹, Jian Zhu ², Jianglin Zhang ² and Feng Huang³, ¹Department of Rheumatology, Chinese PLA GeneralHospital,, Beijing, Beijing, China (People's Republic), ²Chinese People’s Liberation Army General Hospital, Beijing, China (People's Republic), ³Department of Rheumatology, Chinese PLA General Hospital, beijing, China (People's Republic)
Background/Purpose: We developed a multipurpose digital platform, Smart-phone SpondyloArthritis Management System (SpAMS), based on two of the most important objectives: 1) for patients: to activate…
Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Daniele Mauro¹, Federica Macaluso ², Alessandra Nerviani ³, Marie-Astrid Boutet ³, Aroldo Rizzo ⁴, Riccardo Alessandro ², Giuliana Guggino ², Costantino Pitzalis ³ and Francesco Ciccia ⁵, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, ²University of Palermo, Italy, Palermo, Italy, ³Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, ⁵University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
Abstract Number: 434 • 2019 ACR/ARP Annual Meeting
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Cheng-Chung Wei¹, Theresa Hunter ², Filip Van den Bosch ³, Jessica Walsh ⁴, Uta Kiltz ⁵, Yan Dong ⁶, David Sandoval ⁶, Luis Leon ⁶, Vibeke Strand ⁷ and Xiaoqi Li ², ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²Eli Lilly and Company, Indianapolis, ³Ghent University Hospital, Ghent, Belgium, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Previous trials have used the Short Form (SF)-36 questionnaire to evaluate the impact of ankylosing spondylitis/radiographic axial spondyloarthritis (AS/r-axSpA) on health-related quality of life…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].